80_FR_72036 80 FR 71815 - Proposed Collection; 60-Day Comment Request; Drug Accountability Report Form and Investigator Registration Procedure in the Conduct of Investigational Trials for the Treatment of Cancer (NCI) [email protected] Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: Title: Drug Accountability Report Form and Investigator Registration Procedure in the Conduct of Investigational Trials for the Treatment of Cancer, 0925-0613, Expiration Date 03/31/ 2016, Revision, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: Revision. The U.S. Food and Drug Administration (FDA) holds the National Cancer Institute (NCI) responsible, as a sponsor of investigational drug trials, for the collection of information about the clinical investigators who participate in these trials and to assure the FDA that systems for accountability are being maintained by investigators in its clinical trials program. The information collected is used to identify qualified investigators and to facilitate the submission and distribution of important information relative to the investigational drug and the response of the patient to that drug. Investigators are physicians who specialize in the treatment of patients with cancer. Data obtained from the Drug Accountability Record is used to track the dispensing of investigational anticancer agents from receipt from the NCI to dispensing or administration to patients. NCI and/or its auditors use this information for compliance purposes. The frequency of Response is up to 16 times per year. The affected public is private sector including businesses, other for-profit organizations, and non-profit institutions. The type of respondents are investigators, pharmacists, nurses, pharmacy technicians, and data managers. OMB approval is requested for 3 years. There are no capital costs, operating costs or maintenance costs. The total estimated annualized burden hours are 22,645 hours."> [email protected] Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: Title: Drug Accountability Report Form and Investigator Registration Procedure in the Conduct of Investigational Trials for the Treatment of Cancer, 0925-0613, Expiration Date 03/31/ 2016, Revision, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: Revision. The U.S. Food and Drug Administration (FDA) holds the National Cancer Institute (NCI) responsible, as a sponsor of investigational drug trials, for the collection of information about the clinical investigators who participate in these trials and to assure the FDA that systems for accountability are being maintained by investigators in its clinical trials program. The information collected is used to identify qualified investigators and to facilitate the submission and distribution of important information relative to the investigational drug and the response of the patient to that drug. Investigators are physicians who specialize in the treatment of patients with cancer. Data obtained from the Drug Accountability Record is used to track the dispensing of investigational anticancer agents from receipt from the NCI to dispensing or administration to patients. NCI and/or its auditors use this information for compliance purposes. The frequency of Response is up to 16 times per year. The affected public is private sector including businesses, other for-profit organizations, and non-profit institutions. The type of respondents are investigators, pharmacists, nurses, pharmacy technicians, and data managers. OMB approval is requested for 3 years. There are no capital costs, operating costs or maintenance costs. The total estimated annualized burden hours are 22,645 hours." /> [email protected] Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: Title: Drug Accountability Report Form and Investigator Registration Procedure in the Conduct of Investigational Trials for the Treatment of Cancer, 0925-0613, Expiration Date 03/31/ 2016, Revision, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: Revision. The U.S. Food and Drug Administration (FDA) holds the National Cancer Institute (NCI) responsible, as a sponsor of investigational drug trials, for the collection of information about the clinical investigators who participate in these trials and to assure the FDA that systems for accountability are being maintained by investigators in its clinical trials program. The information collected is used to identify qualified investigators and to facilitate the submission and distribution of important information relative to the investigational drug and the response of the patient to that drug. Investigators are physicians who specialize in the treatment of patients with cancer. Data obtained from the Drug Accountability Record is used to track the dispensing of investigational anticancer agents from receipt from the NCI to dispensing or administration to patients. NCI and/or its auditors use this information for compliance purposes. The frequency of Response is up to 16 times per year. The affected public is private sector including businesses, other for-profit organizations, and non-profit institutions. The type of respondents are investigators, pharmacists, nurses, pharmacy technicians, and data managers. OMB approval is requested for 3 years. There are no capital costs, operating costs or maintenance costs. The total estimated annualized burden hours are 22,645 hours." />

80 FR 71815 - Proposed Collection; 60-Day Comment Request; Drug Accountability Report Form and Investigator Registration Procedure in the Conduct of Investigational Trials for the Treatment of Cancer (NCI)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 221 (November 17, 2015)

Page Range71815-71816
FR Document2015-29246

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Cancer Therapy Evaluation Program (CTEP)/Division of Cancer Therapy and Diagnostics (DCTD), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. To Submit Comments and for Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact, Charles Hall, RPh, M.S., Chief, Pharmaceutical Management Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 9609 Medical Center Drive, RM 5W240, MSC 9725, Bethesda, Maryland 20892. Or call non-toll-free number (240) 276-6575, or email your request, include your address to: [email protected] Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: Title: Drug Accountability Report Form and Investigator Registration Procedure in the Conduct of Investigational Trials for the Treatment of Cancer, 0925-0613, Expiration Date 03/31/ 2016, Revision, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: Revision. The U.S. Food and Drug Administration (FDA) holds the National Cancer Institute (NCI) responsible, as a sponsor of investigational drug trials, for the collection of information about the clinical investigators who participate in these trials and to assure the FDA that systems for accountability are being maintained by investigators in its clinical trials program. The information collected is used to identify qualified investigators and to facilitate the submission and distribution of important information relative to the investigational drug and the response of the patient to that drug. Investigators are physicians who specialize in the treatment of patients with cancer. Data obtained from the Drug Accountability Record is used to track the dispensing of investigational anticancer agents from receipt from the NCI to dispensing or administration to patients. NCI and/or its auditors use this information for compliance purposes. The frequency of Response is up to 16 times per year. The affected public is private sector including businesses, other for-profit organizations, and non-profit institutions. The type of respondents are investigators, pharmacists, nurses, pharmacy technicians, and data managers. OMB approval is requested for 3 years. There are no capital costs, operating costs or maintenance costs. The total estimated annualized burden hours are 22,645 hours.

Federal Register, Volume 80 Issue 221 (Tuesday, November 17, 2015) 
[Federal Register Volume 80, Number 221 (Tuesday, November 17, 2015)]
[Notices]
[Pages 71815-71816]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-29246]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Proposed Collection; 60-Day Comment Request; Drug Accountability 
Report Form and Investigator Registration Procedure in the Conduct of 
Investigational Trials for the Treatment of Cancer (NCI)

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of 
the Paperwork Reduction Act of 1995, for opportunity for public comment 
on proposed data collection projects, the Cancer Therapy Evaluation 
Program (CTEP)/Division of Cancer Therapy and Diagnostics (DCTD), the 
National Institutes of Health (NIH) will publish periodic summaries of 
proposed projects to be submitted to the Office of Management and 
Budget (OMB) for review and approval.
    Written comments and/or suggestions from the public and affected 
agencies are invited to address one or more of the following points: 
(1) Whether the proposed collection of information is necessary for the 
proper performance of the function of the agency, including whether the 
information will have practical utility; (2) The accuracy of the 
agency's estimate of the burden of the proposed collection of 
information, including the validity of the methodology and assumptions 
used; (3) The quality, utility, and clarity of the information to be 
collected; and (4) Minimize the burden of the collection of information 
on those who are to respond, including the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology.
    To Submit Comments and for Further Information: To obtain a copy of 
the data collection plans and instruments, submit comments in writing, 
or request more information on the proposed project, contact, Charles 
Hall, RPh, M.S., Chief, Pharmaceutical Management Branch, Cancer 
Therapy Evaluation Program, National Cancer Institute, 9609 Medical 
Center Drive, RM 5W240, MSC 9725, Bethesda, Maryland 20892. Or call 
non-toll-free number (240) 276-6575, or email your request, include 
your address to: [email protected].
    Comment Due Date: Comments regarding this information collection 
are best assured of having their full effect if received within 60 days 
of the date of this publication.
    Proposed Collection: Title: Drug Accountability Report Form and 
Investigator Registration Procedure in the Conduct of Investigational 
Trials for the Treatment of Cancer, 0925-0613, Expiration Date 03/31/
2016, Revision, National Cancer Institute (NCI), National Institutes of 
Health (NIH).
    Need and Use of Information Collection: Revision. The U.S. Food and 
Drug Administration (FDA) holds the National Cancer Institute (NCI) 
responsible, as a sponsor of investigational drug trials, for the 
collection of information about the clinical investigators who 
participate in these trials and to assure the FDA that systems for 
accountability are being maintained by investigators in its clinical 
trials program. The information collected is used to identify qualified 
investigators and to facilitate the submission and distribution of 
important information relative to the investigational drug and the 
response of the patient to that drug. Investigators are physicians who 
specialize in the treatment of patients with cancer. Data obtained from 
the Drug Accountability Record is used to track the dispensing of 
investigational anticancer agents from receipt from the NCI to 
dispensing or administration to patients. NCI and/or its auditors use 
this information for compliance purposes. The frequency of Response is 
up to 16 times per year. The affected public is private sector 
including businesses, other for-profit organizations, and non-profit 
institutions. The type of respondents are investigators, pharmacists, 
nurses, pharmacy technicians, and data managers.
    OMB approval is requested for 3 years. There are no capital costs, 
operating costs or maintenance costs. The total estimated annualized 
burden hours are 22,645 hours.

Estimated Annualized Burden Hours

[[Page 71816]]



                                       Table 1--Estimates of Annual Burden
----------------------------------------------------------------------------------------------------------------
                                                                                   Average time
      Type of respondents             Form           Number of     Frequency of    per response     Total hour
                                                    respondents      response       (in hours)        burden
----------------------------------------------------------------------------------------------------------------
Investigators and Designee for  Statement of              22,283               1           15/60           5,571
 Investigator Registration and   Investigator
 DARF.                           (Attachments
                                 3A, 3B or 10).
                                NCI/DCTD/CTEP             22,283               1           10/60           3,721
                                 Supplemental
                                 Investigator
                                 (Attachment 4).
                                Financial                 22,283               1            5/60           1,849
                                 Disclosure
                                 Forms
                                 (Attachment 5A
                                 or 5B).
                                NCI/DCTD/CTEP              3,288              16            4/60           3,525
                                 Drug
                                 Accountability
                                 Record Form
                                 (DARF and DARF-
                                 Oral)
                                 (Attachments 1
                                 & 2).
----------------------------------------------------------------------------------------------------------------


    Dated: November 9, 2015.
Karla Bailey,
Project Clearance Liaison, National Cancer Institute, NIH.
[FR Doc. 2015-29246 Filed 11-16-15; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices 71815 DEPARTMENT OF HEALTH AND 93.333, Clinical Research, 93.306, 93.333, Chief, Pharmaceutical Management HUMAN SERVICES 93.337, 93.393–93.396, 93.837–93.844, Branch, Cancer Therapy Evaluation 93.846–93.878, 93.892, 93.893, National Program, National Cancer Institute, 9609 National Institutes of Health Institutes of Health, HHS) Medical Center Drive, RM 5W240, MSC Dated: November 10, 2015. 9725, Bethesda, Maryland 20892. Or call Center for Scientific Review; Notice of Natasha Copeland, non-toll-free number (240) 276–6575, or Closed Meetings Program Analyst, Office of Federal Advisory email your request, include your Pursuant to section 10(d) of the Committee Policy. address to: hallch@mail.nih.gov. Federal Advisory Committee Act, as [FR Doc. 2015–29243 Filed 11–16–15; 8:45 am] Comment Due Date: Comments amended (5 U.S.C. App.), notice is BILLING CODE 4140–01–P regarding this information collection are hereby given of the following meetings. best assured of having their full effect if The meetings will be closed to the received within 60 days of the date of public in accordance with the DEPARTMENT OF HEALTH AND this publication. provisions set forth in sections HUMAN SERVICES Proposed Collection: Title: Drug 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Accountability Report Form and National Institutes of Health as amended. The grant applications and Investigator Registration Procedure in the discussions could disclose Proposed Collection; 60-Day Comment the Conduct of Investigational Trials for confidential trade secrets or commercial Request; Drug Accountability Report the Treatment of Cancer, 0925–0613, property such as patentable material, Form and Investigator Registration Expiration Date 03/31/2016, Revision, and personal information concerning Procedure in the Conduct of National Cancer Institute (NCI), individuals associated with the grant Investigational Trials for the Treatment National Institutes of Health (NIH). applications, the disclosure of which of Cancer (NCI) would constitute a clearly unwarranted Need and Use of Information invasion of personal privacy. SUMMARY: In compliance with the Collection: Revision. The U.S. Food and requirement of Section 3506(c)(2)(A) of Drug Administration (FDA) holds the Name of Committee: Center for Scientific National Cancer Institute (NCI) Review Special Emphasis Panel; Member the Paperwork Reduction Act of 1995, Conflict: Topics in Digestive Disease. for opportunity for public comment on responsible, as a sponsor of Date: November 23, 2015. proposed data collection projects, the investigational drug trials, for the Time: 2:00 p.m. to 4:30 p.m. Cancer Therapy Evaluation Program collection of information about the Agenda: To review and evaluate grant (CTEP)/Division of Cancer Therapy and clinical investigators who participate in applications. Diagnostics (DCTD), the National these trials and to assure the FDA that Place: National Institutes of Health, 6701 Institutes of Health (NIH) will publish systems for accountability are being Rockledge Drive, Bethesda, MD 20892, periodic summaries of proposed maintained by investigators in its (Telephone Conference Call). projects to be submitted to the Office of clinical trials program. The information Contact Person: Aiping Zhao, MD., Scientific Review Officer, Center for Management and Budget (OMB) for collected is used to identify qualified Scientific Review, National Institutes of review and approval. investigators and to facilitate the Health, 6701 Rockledge Drive, Rm 2188 Written comments and/or suggestions submission and distribution of MSC7818, Bethesda, MD 20892–7818, (301) from the public and affected agencies important information relative to the 435–0682, zhaoa2@csr.nih.gov. are invited to address one or more of the investigational drug and the response of This notice is being published less than 15 following points: (1) Whether the the patient to that drug. Investigators are days prior to the meeting due to the timing proposed collection of information is physicians who specialize in the limitations imposed by the review and necessary for the proper performance of treatment of patients with cancer. Data funding cycle. the function of the agency, including obtained from the Drug Accountability Name of Committee: Center for Scientific whether the information will have Record is used to track the dispensing Review Special Emphasis Panel; Member practical utility; (2) The accuracy of the of investigational anticancer agents from Conflict: Oncology 2—Translational Clinical agency’s estimate of the burden of the Applications. receipt from the NCI to dispensing or proposed collection of information, administration to patients. NCI and/or Date: November 24, 2015. Time: 11:00 a.m. to 1:00 p.m. including the validity of the its auditors use this information for Agenda: To review and evaluate grant methodology and assumptions used; (3) compliance purposes. The frequency of applications. The quality, utility, and clarity of the Response is up to 16 times per year. The Place: National Institutes of Health, 6701 information to be collected; and (4) affected public is private sector Rockledge Drive, Bethesda, MD 20892, Minimize the burden of the collection of including businesses, other for-profit (Telephone Conference Call). information on those who are to organizations, and non-profit Contact Person: Sharon K. Gubanich, respond, including the use of Ph.D., Scientific Review Officer, Center for institutions. The type of respondents are appropriate automated, electronic, investigators, pharmacists, nurses, Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6195D, mechanical, or other technological pharmacy technicians, and data MSC 7804, Bethesda, MD 20892, (301) 408– collection techniques or other forms of managers. 9512, gubanics@csr.nih.gov. information technology. OMB approval is requested for 3 This notice is being published less than 15 To Submit Comments and for Further years. There are no capital costs, days prior to the meeting due to the timing Information: To obtain a copy of the operating costs or maintenance costs. limitations imposed by the review and data collection plans and instruments, The total estimated annualized burden mstockstill on DSK4VPTVN1PROD with NOTICES funding cycle. submit comments in writing, or request hours are 22,645 hours. (Catalogue of Federal Domestic Assistance more information on the proposed Program Nos. 93.306, Comparative Medicine; project, contact, Charles Hall, RPh, M.S., Estimated Annualized Burden Hours VerDate Sep<11>2014 18:14 Nov 16, 2015 Jkt 238001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\17NON1.SGM 17NON1

71816 Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices TABLE 1—ESTIMATES OF ANNUAL BURDEN Average time Number of Frequency of Total hour Type of respondents Form per response respondents response burden (in hours) Investigators and Designee for In- Statement of Investigator (Attach- 22,283 1 15/60 5,571 vestigator Registration and DARF. ments 3A, 3B or 10). NCI/DCTD/CTEP Supplemental In- 22,283 1 10/60 3,721 vestigator (Attachment 4). Financial Disclosure Forms (Attach- 22,283 1 5/60 1,849 ment 5A or 5B). NCI/DCTD/CTEP Drug Account- 3,288 16 4/60 3,525 ability Record Form (DARF and DARF-Oral) (Attachments 1 & 2). Dated: November 9, 2015. Emphasis Panel; NIAID Resource-Related decide whether NCI should support Karla Bailey, Research Projects (R24) and NIAID requests and make available contract Investigator Initiated Program Project resources for development of the Project Clearance Liaison, National Cancer Applications (P01). Institute, NIH. potential therapeutic to improve the Date: January 12–13, 2016. [FR Doc. 2015–29246 Filed 11–16–15; 8:45 am] Time: 12:00 p.m. to 5:00 p.m. treatment of various forms of cancer. BILLING CODE 4140–01–P Agenda: To review and evaluate grant The research proposals and the applications. discussions could disclose confidential Place: National Institutes of Health, Room trade secrets or commercial property DEPARTMENT OF HEALTH AND 3F100, 5601 Fishers Lane, Rockville, MD such as patentable material, and HUMAN SERVICES 20892 (Telephone Conference Call). personal information concerning Contact Person: Quirijn Vos, Ph.D., individuals associated with the National Institutes of Health Scientific Review Officer, Scientific Review proposed research projects, the Program, Division of Extramural Activities, Room 3G31A, National Institutes of Health/ disclosure of which would constitute a National Institute of Allergy and clearly unwarranted invasion of Infectious Diseases: Notice of Closed NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5059, personal privacy. Meetings qvos@niaid.nih.gov. Name of Committee: National Cancer Pursuant to section 10(d) of the (Catalogue of Federal Domestic Assistance Institute Special Emphasis Panel; Dec 2015 Federal Advisory Committee Act, as Program Nos. 93.855, Allergy, Immunology, Cycle 21 NExT SEP Committee Meeting. amended (5 U.S.C. App.), notice is and Transplantation Research; 93.856, Date: December 16, 2015. hereby given of the following meetings. Microbiology and Infectious Diseases Time: 8:30 a.m. to 4:30 p.m. The meetings will be closed to the Research, National Institutes of Health, HHS) Agenda: To evaluate the NCI Experimental public in accordance with the Dated: November 9, 2015. Therapeutics Program Portfolio. provisions set forth in sections Natasha Copeland, Place: National Institutes of Health, 9000 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Rockville Pike, Campus Building 31, Program Analyst, Office of Federal Advisory as amended. The grant applications and Conference Room 6C6, Bethesda, MD 20892. Committee Policy. the discussions could disclose Contact Person: Barbara Mroczkowski, [FR Doc. 2015–29247 Filed 11–16–15; 8:45 am] Ph.D., Executive Secretary, Discovery confidential trade secrets or commercial property such as patentable material, BILLING CODE 4140–01–P Experimental Therapeutics Program National Cancer Institute, NIH, 31 Center Drive, Room and personal information concerning 3A44, Bethesda, MD 20817, (301) 496–4291, individuals associated with the grant DEPARTMENT OF HEALTH AND mroczkoskib@mail.nih.gov. applications, the disclosure of which HUMAN SERVICES Toby Hecht, Ph.D., Executive Secretary, would constitute a clearly unwarranted Development Experimental Therapeutics invasion of personal privacy. National Institutes of Health Program, National Cancer Institute, NIH, Name of Committee: National Institute of 9609 Medical Center Drive, Room 3W110, Allergy and Infectious Diseases Special National Cancer Institute; Notice of Rockville, MD 20850, (240) 276–5683 Emphasis Panel; NIAID SBIR Phase II Closed Meeting toby.hecht2@nih.gov. Clinical Trial Implementation Cooperative (Catalogue of Federal Domestic Assistance Agreement (U44). Pursuant to section 10(d) of the Federal Advisory Committee Act, as Program Nos. 93.392, Cancer Construction; Date: December 9, 2015. 93.393, Cancer Cause and Prevention Time: 9:00 a.m. to 2:00 p.m. amended (5 U.S.C. Appendix 2); notice Research; 93.394, Cancer Detection and Agenda: To review and evaluate grant is hereby given of the following Diagnosis Research; 93.395, Cancer applications. meeting. Treatment Research; 93.396, Cancer Biology Place: National Institutes of Health, Room The meeting will be closed to the 4C100, 5601 Fishers Lane, Rockville, MD Research; 93.397, Cancer Centers Support; public in accordance with the 93.398, Cancer Research Manpower; 93.399, 20892. provisions set forth in sections Contact Person: Zhuqing (Charlie) Li, Cancer Control, National Institutes of Health, mstockstill on DSK4VPTVN1PROD with NOTICES 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., HHS) Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural as amended. The purpose of this meeting is to evaluate requests for Dated: November 10, 2015. Activities, Room # 3G41B, National Institutes preclinical development resources for Melanie J. Gray, of Health/NIAID, 5601 Fishers Lane, MSC9823, Bethesda, MD 20892–9823, (240) potential new therapeutics for the Program Analyst, Office of Federal Advisory 669–5068, zhuqing.li@nih.gov. treatment of cancer. The outcome of the Committee Policy. Name of Committee: National Institute of evaluation will provide information to [FR Doc. 2015–29245 Filed 11–16–15; 8:45 am] Allergy and Infectious Diseases Special internal NCI committees that will BILLING CODE 4140–01–P VerDate Sep<11>2014 18:14 Nov 16, 2015 Jkt 238001 PO 00000 Frm 00047 Fmt 4703 Sfmt 9990 E:\FR\FM\17NON1.SGM 17NON1


Document Created: 2015-12-14 14:01:25
Document Modified: 2015-12-14 14:01:25
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesComments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.
FR Citation80 FR 71815 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR